The absence of associations between STING immunostaining and parameters of cancer aggressiveness in gastric adenocarcinomas, high-grade serous and endometrioid ovarian cancer, endometrioid endometrial carcinoma, pancreatic adenocarcinoma, and papillary RCC further demonstrates that the level of STING expression in tumor cells is not likely to represent a pivotal general feature of cancer aggressiveness. This evidence concerns the gene STING1 and cancer.